论文部分内容阅读
目的分析宫颈癌新辅助化疗前后患者Survivin、血管内皮生长因子(VEGF)和Ki-67的变化及其临床意义。方法随机选取2015年1月1日至2016年1月1日收治的50例接受新辅助化疗的宫颈癌患者,给予所有患者两个疗程的卡铂+紫杉醇联合化疗(TC化疗)。观察患者治疗前后的Survivin、VEGF和Ki-67的变化,并总结其临床意义。结果新辅助化疗后的Survivin阳性率(34.00%)、VEGF阳性率(22.00%)、Ki-67阳性率(20.00%)均低于化疗前的Survivin阳性率(78.00%)、VEGF阳性率(74.00%)和Ki-67阳性率(76.00%),差异均具有统计学意义(P均<0.01)。50例患者经新辅助化疗后,完全缓解7例,部分缓解33例,无效9例,进展1例,治疗有效率为80.00%。Survivin、VEGF、Ki-67阳性患者在完全缓解、部分缓解、无效、进展中的分布差异均具有统计学意义(P均<0.01)。结论宫颈癌新辅助化疗后,Survivin、VEGF和Ki-67三种指标阳性率均较治疗前有显著下降,且病情越重者该三种指标阳性率越高,提示Survivin、VEGF和Ki-67可用于宫颈癌病情的预估和治疗的评价。
Objective To analyze the changes of Survivin, vascular endothelial growth factor (VEGF) and Ki-67 in patients with cervical cancer before and after neoadjuvant chemotherapy and their clinical significance. Methods Fifty patients with cervical cancer who underwent neoadjuvant chemotherapy were enrolled from January 1, 2015 to January 1, 2016. All patients received two cycles of combined carboplatin and paclitaxel chemotherapy (TC chemotherapy). The changes of Survivin, VEGF and Ki-67 in patients before and after treatment were observed and their clinical significance was summarized. Results The positive rates of Survivin (34.00%), VEGF (22.00%) and Ki-67 (20.00%) after neoadjuvant chemotherapy were lower than those before chemotherapy (78.00% %) And Ki-67 positive rate (76.00%), the differences were statistically significant (all P <0.01). After neoadjuvant chemotherapy in 50 patients, complete remission in 7 cases, partial remission in 33 cases, ineffective in 9 cases, 1 case of progress, the effective rate was 80.00%. The distribution of Survivin, VEGF, Ki-67 positive patients in complete remission, partial remission, ineffective, and progressive differences were statistically significant (all P <0.01). Conclusions After neoadjuvant chemotherapy for cervical cancer, the positive rates of Survivin, VEGF and Ki-67 are significantly lower than those before treatment, and the higher the positive rates of these three indexes are, the higher rates of Survivin, VEGF and Ki-67 Can be used for cervical cancer prognosis and treatment evaluation.